{"name":"Intra-Cellular Therapies","slug":"intra-cellular","ticker":"ITCI","exchange":"NASDAQ","domain":"intracellulartherapies.com","description":"Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on the development of innovative treatments for complex psychiatric and neurologic disorders. The company's pipeline includes several promising candidates, including lumateperone, which has received FDA approval for the treatment of schizophrenia. ITCI's therapeutic focus is on the central nervous system (CNS) and psychiatry, with a goal of addressing unmet medical needs in these areas. The company has established itself as a key player in the CNS/pharmacology space.","hq":"New York, NY","founded":2006,"employees":"~75,000","ceo":"Sharon Mates","sector":"CNS / Psychiatry","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"2.3B","metrics":{"revenue":900000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Caplyta","genericName":"LUMATEPERONE","slug":"lumateperone","revenue":900000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2019-01-01","label":"Caplyta first approved","drug":"Caplyta","drugSlug":"lumateperone","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-06-01","label":"lumateperone patent cliff ($0.0B at risk)","drug":"lumateperone","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":900000000,"percentOfTotal":100,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Caplyta","genericName":"LUMATEPERONE","slug":"lumateperone","indication":"Schizophrenia","status":"marketed","revenue":900000000},{"name":"ITI-007 (Lumateperone)","genericName":"ITI-007 (Lumateperone)","slug":"iti-007-lumateperone","indication":"Schizophrenia (acute and maintenance treatment)","status":"phase_3"},{"name":"Lumateperone (ITI-007)","genericName":"Lumateperone (ITI-007)","slug":"lumateperone-iti-007","indication":"Schizophrenia","status":"phase_3"},{"name":"Lumateperone high dose","genericName":"Lumateperone high dose","slug":"lumateperone-high-dose","indication":"Schizophrenia (phase 3)","status":"phase_3"},{"name":"Lumateperone low dose","genericName":"Lumateperone low dose","slug":"lumateperone-low-dose","indication":"Schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"Caplyta","genericName":"LUMATEPERONE","slug":"lumateperone","phase":"marketed","mechanism":"Caplyta works by binding to the 5-hydroxytryptamine receptor 2A, which helps to regulate dopamine and serotonin levels in the brain.","indications":["Schizophrenia"],"catalyst":""},{"name":"ITI-007 (Lumateperone)","genericName":"ITI-007 (Lumateperone)","slug":"iti-007-lumateperone","phase":"phase_3","mechanism":"Lumateperone is a serotonin 5-HT7 receptor antagonist and phosphodiesterase 1 inhibitor that modulates intracellular signaling pathways implicated in psychosis and mood disorders.","indications":["Schizophrenia (acute and maintenance treatment)","Bipolar disorder (in development)"],"catalyst":""},{"name":"Lumateperone (ITI-007)","genericName":"Lumateperone (ITI-007)","slug":"lumateperone-iti-007","phase":"phase_3","mechanism":"Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.","indications":["Schizophrenia","Bipolar depression"],"catalyst":""},{"name":"Lumateperone high dose","genericName":"Lumateperone high dose","slug":"lumateperone-high-dose","phase":"phase_3","mechanism":"Lumateperone is a serotonin 5-HT7 receptor antagonist and phosphodiesterase 10 (PDE10) inhibitor that modulates dopamine and glutamate signaling in the brain.","indications":["Schizophrenia (phase 3)","Bipolar depression (phase 3)"],"catalyst":""},{"name":"Lumateperone low dose","genericName":"Lumateperone low dose","slug":"lumateperone-low-dose","phase":"phase_3","mechanism":"Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.","indications":["Schizophrenia"],"catalyst":""}],"recentEvents":[{"date":"2023-05-25","type":"regulatory","headline":"ITCI Announces FDA Approval of Lumateperone for Treatment of Schizophrenia","summary":"The FDA has approved lumateperone for the treatment of schizophrenia in adults.","drugName":"lumateperone","sentiment":"positive"},{"date":"2022-02-24","type":"earnings","headline":"ITCI Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"ITCI reported revenue of $13.4 million for the fourth quarter of 2021, a 24% increase from the same period in 2020.","drugName":"","sentiment":"neutral"},{"date":"2021-06-14","type":"deal","headline":"ITCI Announces Collaboration with Janssen Pharmaceuticals to Develop and Commercialize Lumateperone","summary":"ITCI has entered into a collaboration with Janssen Pharmaceuticals to develop and commercialize lumateperone for the treatment of schizophrenia and bipolar depression.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMzliRzhnVW9tY1h3eGpOdDBiSmhaSThZRkF0RmYtSFJQMGY5N2VuNWhRWm9tX3BJWmJvQjZBS0lVLV9hX3pkRFFyZzRNS3pxU2F2N3Z3cDRpYV9EbE1hQjhuSGt0WXUyMFBqZW4wT3QtNWVXRXl0UHktaGtURXRTU1R3R2VnV0dNNnlhZnFwY0U4aGRxMTlXZjhYWFE4SmFOM0YtX0FaRHVrSlA3NjRVS0lQdV9WTXcxQ2hF?oc=5","date":"2025-02-07","type":"regulatory","source":"Fierce Pharma","summary":"J&J CEO broke a stalemate and facilitated the $14.6B Intra-Cellular buyout in a whirlwind month: filing - Fierce Pharma","headline":"J&J CEO broke a stalemate and facilitated the $14.6B Intra-Cellular buyout in a whirlwind month: filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOcm9hTFY4U2tQQUdlcTdBTURjVWdtRV9Qb29ZZmNtQk9CSUF5WDZLMDJVT2ZTaV81MGNFalFGbUNxckJuQTRLN0xtZHk1SXFOY2lrRXZNUkMtX21ac2tmNS1PN3RaZ2lTdW5KNUxwUE9LMmgxc2RVbV9CT1FnRm95S1lWalNGZw?oc=5","date":"2025-01-14","type":"deal","source":"Yahoo Finance","summary":"Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - Yahoo Finance","headline":"Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE8wYjQ0dWxVSlNNYlAwNmQxZUNQOWZXRDZXa09oNUxHRnd0b2JWVTk1OVhCaHdaZzRvYkllTk5FdXNGQzA4Qk9ZSU9KcnEwUFIySS1uWU9yTm8tdnA1elJLRy1PVVR4ZE9oNnliNHhMMUppZjg?oc=5","date":"2025-01-14","type":"pipeline","source":"investingnews.com","summary":"Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition - investingnews.com","headline":"Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQNmNjMzMxUl9OWHV0UEFOb3lva1dQRm5HZVFQUm5CeDJObXR5M0FNeElrY3Z3S2RIcEFQSlg5SG8xbTd3b3hEOXZHTkZhajN4QWFrYXdDTTh2UmNsUEpVUUhEUG5RcnQxaTdmUG5qeTA1a0xXSHAzNDA0VWJqUkFlb3NJX25EaWxiQjNpT0JMMlhUT2EzamExRA?oc=5","date":"2025-01-13","type":"deal","source":"Reuters","summary":"J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal - Reuters","headline":"J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQUnRuTzdlcDdITWRJdVVPSnlMUXlscHhBaGFLU1c0WmZrSnl5aWVIMFR5TnVMakgtREh0Y3hNVkhhZndEQUhiX1NWSElEam9kZFN0aFBvUVRGU0toVTlwcE9CM2Rrc2sxbDZOLWVYRmw0ei1zX1NqQ1VjSUN5TFY2V1lNVUlUdFXSAYwBQVVfeXFMT1hXRjZPSlNHRkV5OG5fS3JIVlVudU9QWlAybnRJMFlyQW5HMmJIUmMwd1dOZEhhb2wwUnlrMEVCUTUzRlZKd21IS09CeFVsY294ZTd5MkxlbldkREFwN1NXdWo0TjRwMV94THZ0VTQzTnpHei03R1M0ZU5uazVBTnZ3UTFHN1ZmZGJpSzg?oc=5","date":"2025-01-13","type":"deal","source":"cnbc.com","summary":"J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion - cnbc.com","headline":"J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNbmJMc2tnOFVOZUs3Q1E4UjNBU29Uc0J4LWxnUzlCZXpNWmY2MWVnNUx3aU9hdVlUZ2FGSDVjSGJ0V3RDdHJGNGlsb2I4c3J5dFI4dDU5S09CM3M5a1lIeEVIc1hRUk0yQ3kweEVRcGlKTmRoRFZZajdiOWJVY2ZGRkRRV0RTS3A0VDBta04wNzlKTzhDSVN1MWpsYTEwT0hMRE5VRXl0bzE5WkQ3?oc=5","date":"2025-01-13","type":"deal","source":"BioPharma Dive","summary":"J&J to buy psychiatric drug developer Intra-Cellular for $14.6B - BioPharma Dive","headline":"J&J to buy psychiatric drug developer Intra-Cellular for $14.6B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQZWRSQTlkcDdMOTNQSExLSy1lV24yQm13eDZuVEkzdXZpY1VPWDc1NF9aRDd1T0ZKSEFSTDFidC1vX055TE9UYUpBOERCVXJPUUN3OTF4NmVzenNpdWR4Y1czR19YYlpOaFd2Y2VzTjdJekxpeno3LWRZemR3R2ZkN1lMeWFfQ3BTalNYdjJyeXdpODRORTJHMVFISS04UQ?oc=5","date":"2025-01-13","type":"deal","source":"The Pharma Letter","summary":"J&J punts $14.6 billion on buy of Intra-Cellular Therapies - The Pharma Letter","headline":"J&J punts $14.6 billion on buy of Intra-Cellular Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUEE3WkZLZTRjSWI5cnhBdkNxT2NOR2pqOGpmdW1zZElSUnhGdFhnNm5FTjlWTUE2RmhGUlcteDY3aXpLWmx0aHBITkhQR29PMVZ5QUZGMHZZbFZVSWlKTGRuSlZfcTJaOXRZcThOa2dfOUQyelcxMDFQaXJzcC1zT2ViMkRhZV83UVpwX0tMM1NWYlkwQXpOeDNLWWk2aTNSdlpURnpSb2RpeVI1d2xRTTJtVTVvMllfRzBGRQ?oc=5","date":"2025-01-13","type":"deal","source":"MedCity News","summary":"J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies - MedCity News","headline":"J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPLV9ZTUFhVnNnQzNNM3R1NDZBY0ZzUXRCeHlpSkptVDRKWFpxd0Y0cnVYRlhqREJySlhOcXhWeG1FX2hoOG1keFNnMU80WjBDT016ZFA5b2ZFV2YtNWs0dXFMVUdhSUlSd0dCWmE5cTQxUEI4NW9KMXFTZ0ExczdhWmYzS3M5RVVlNTMxTnhBZTZOa24zMW5ZRWNBcjlMbjdi?oc=5","date":"2025-01-13","type":"deal","source":"bloomberg.com","summary":"J&J to Acquire Intra-Cellular for About $14.6 Billion - bloomberg.com","headline":"J&J to Acquire Intra-Cellular for About $14.6 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVVhZNWFDMmVoUWFzV0N1eEhRUkJudG5IYmhTbWdTWGdtYmdZaUlFWHFJdmRqTU9yYUxneHZsbGZ3VnNPNHliMXdzSWlJcVJFQUxjU3BEUGhnVldrNUJMRC1mcVoxQm5ucm43UEN6WGhXS3dSdlhycTZmaENiNGoxTFBpbU1qdGhuSU5BdTNzRU1Lb2NxOV9IblBOWk1Rc0ZIWldvU0NzblRKS1lJUlBTLUdTaGhDZTRtdW9HZGI3SzBhMUE?oc=5","date":"2025-01-13","type":"pipeline","source":"Seeking Alpha","summary":"What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies (ITCI) - Seeking Alpha","headline":"What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies (ITCI)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNaGxpcmtBU1ZuLThpb3JrN0diLWJyN08yVndTN2pON3B6WXRsZDMyWUs0VkpCTG41V2IxN0ZjTlk2U2JLVjlGemZUMEIwdnF5cUJiOG5HbUlnRnhnSms4MUU4alRsX1dxbENKQUg2dVA4clB3UzNmLWlObEhsZlg2TFdEWDFrV3RpS05lZEN5a1hwZElKNFJiV05qeDlfLWUt?oc=5","date":"2025-01-13","type":"deal","source":"Fierce Pharma","summary":"JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B - Fierce Pharma","headline":"JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOdHBiQV9JbDRobmQ4cHpWSmlKbGRTczNxNWVJRGpHcWg4Z2VLaThUS2dlSmxrSHk0ZVUwcG9EQ2Qwa1NjcUhtdUtQNjNhcjlsWHVJMDZXZUVmVVhZVTBXUG9mNUtteHJMNWlfNWMzc2pDYlh0c2pvWXhOTlhFS3FieXVHZXNNdHNFSWlBWU5jVmo3QkJYUUNIN2drdnJZcVFCd3dVMzRXVFhEM25sQU13WE5B?oc=5","date":"2024-03-20","type":"pipeline","source":"Contract Pharma","summary":"Intra-Cellular Therapies Promotes Dr. Michael Halstead to President - Contract Pharma","headline":"Intra-Cellular Therapies Promotes Dr. Michael Halstead to President","sentiment":"neutral"}],"patents":[{"drugName":"lumateperone","drugSlug":"lumateperone","patentNumber":"","type":"Patent Cliff","expiryDate":"2038-06-01","territory":"US","annualRevenue":0}],"drugCount":5,"phaseCounts":{"marketed":1,"phase_3":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alkermes","Neurocrine Biosciences","Pfizer"],"therapeuticFocus":["Central Nervous System (CNS)","Psychiatry"],"financials":null,"yahoo":null}